169 related articles for article (PubMed ID: 35567427)
21. SH-SY5Y-derived neurons: a human neuronal model system for investigating TAU sorting and neuronal subtype-specific TAU vulnerability.
Bell M; Zempel H
Rev Neurosci; 2022 Jan; 33(1):1-15. PubMed ID: 33866701
[TBL] [Abstract][Full Text] [Related]
22. Decrease of neuronal FKBP4/FKBP52 modulates perinuclear lysosomal positioning and MAPT/Tau behavior during MAPT/Tau-induced proteotoxic stress.
Chambraud B; Daguinot C; Guillemeau K; Genet M; Dounane O; Meduri G; Poüs C; Baulieu EE; Giustiniani J
Autophagy; 2021 Nov; 17(11):3491-3510. PubMed ID: 33459145
[TBL] [Abstract][Full Text] [Related]
23. The Human Tau Interactome: Binding to the Ribonucleoproteome, and Impaired Binding of the Proline-to-Leucine Mutant at Position 301 (P301L) to Chaperones and the Proteasome.
Gunawardana CG; Mehrabian M; Wang X; Mueller I; Lubambo IB; Jonkman JE; Wang H; Schmitt-Ulms G
Mol Cell Proteomics; 2015 Nov; 14(11):3000-14. PubMed ID: 26269332
[TBL] [Abstract][Full Text] [Related]
24. Impact of the cellular prion protein on amyloid-β and 3PO-tau processing.
Schmitz M; Wulf K; Signore SC; Schulz-Schaeffer WJ; Kermer P; Bähr M; Wouters FS; Zafar S; Zerr I
J Alzheimers Dis; 2014; 38(3):551-65. PubMed ID: 24028865
[TBL] [Abstract][Full Text] [Related]
25. A post-translational modification signature defines changes in soluble tau correlating with oligomerization in early stage Alzheimer's disease brain.
Ercan-Herbst E; Ehrig J; Schöndorf DC; Behrendt A; Klaus B; Gomez Ramos B; Prat Oriol N; Weber C; Ehrnhoefer DE
Acta Neuropathol Commun; 2019 Dec; 7(1):192. PubMed ID: 31796124
[TBL] [Abstract][Full Text] [Related]
26. Tau truncation is a productive posttranslational modification of neurofibrillary degeneration in Alzheimer's disease.
Kovacech B; Novak M
Curr Alzheimer Res; 2010 Dec; 7(8):708-16. PubMed ID: 20678071
[TBL] [Abstract][Full Text] [Related]
27. Downregulation of miR-132/212 impairs S-nitrosylation balance and induces tau phosphorylation in Alzheimer's disease.
Wang Y; Veremeyko T; Wong AH; El Fatimy R; Wei Z; Cai W; Krichevsky AM
Neurobiol Aging; 2017 Mar; 51():156-166. PubMed ID: 28089352
[TBL] [Abstract][Full Text] [Related]
28. Characterization of the Tau Interactome in Human Brain Reveals Isoform-Dependent Interaction with 14-3-3 Family Proteins.
Betters RK; Luhmann E; Gottschalk AC; Xu Z; Shin MR; Ptak CP; Fiock KL; Radoshevich LC; Hefti MM
eNeuro; 2023 Mar; 10(3):. PubMed ID: 36898832
[TBL] [Abstract][Full Text] [Related]
29. Extracellular Vesicles Isolated from Familial Alzheimer's Disease Neuronal Cultures Induce Aberrant Tau Phosphorylation in the Wild-Type Mouse Brain.
Aulston B; Liu Q; Mante M; Florio J; Rissman RA; Yuan SH
J Alzheimers Dis; 2019; 72(2):575-585. PubMed ID: 31594233
[TBL] [Abstract][Full Text] [Related]
30. Beta-amyloid treatment of two complementary P301L tau-expressing Alzheimer's disease models reveals similar deregulated cellular processes.
David DC; Ittner LM; Gehrig P; Nergenau D; Shepherd C; Halliday G; Götz J
Proteomics; 2006 Dec; 6(24):6566-77. PubMed ID: 17111439
[TBL] [Abstract][Full Text] [Related]
31. Endoplasmic reticulum stress induces tau pathology and forms a vicious cycle: implication in Alzheimer's disease pathogenesis.
Ho YS; Yang X; Lau JC; Hung CH; Wuwongse S; Zhang Q; Wang J; Baum L; So KF; Chang RC
J Alzheimers Dis; 2012; 28(4):839-54. PubMed ID: 22101233
[TBL] [Abstract][Full Text] [Related]
32. Modulation of neurosteroid production in human neuroblastoma cells by Alzheimer's disease key proteins.
Schaeffer V; Patte-Mensah C; Eckert A; Mensah-Nyagan AG
J Neurobiol; 2006 Jul; 66(8):868-81. PubMed ID: 16673391
[TBL] [Abstract][Full Text] [Related]
33. Ebselen ameliorates β-amyloid pathology, tau pathology, and cognitive impairment in triple-transgenic Alzheimer's disease mice.
Xie Y; Tan Y; Zheng Y; Du X; Liu Q
J Biol Inorg Chem; 2017 Aug; 22(6):851-865. PubMed ID: 28502066
[TBL] [Abstract][Full Text] [Related]
34. Acetylation changes tau interactome to degrade tau in Alzheimer's disease animal and organoid models.
Choi H; Kim HJ; Yang J; Chae S; Lee W; Chung S; Kim J; Choi H; Song H; Lee CK; Jun JH; Lee YJ; Lee K; Kim S; Sim HR; Choi YI; Ryu KH; Park JC; Lee D; Han SH; Hwang D; Kyung J; Mook-Jung I
Aging Cell; 2020 Jan; 19(1):e13081. PubMed ID: 31763743
[TBL] [Abstract][Full Text] [Related]
35. Death-associated protein kinase 1 has a critical role in aberrant tau protein regulation and function.
Kim BM; You MH; Chen CH; Lee S; Hong Y; Hong Y; Kimchi A; Zhou XZ; Lee TH
Cell Death Dis; 2014 May; 5(5):e1237. PubMed ID: 24853415
[TBL] [Abstract][Full Text] [Related]
36. Tau phosphorylation during apoptosis of human SH-SY5Y neuroblastoma cells.
Mookherjee P; Johnson GV
Brain Res; 2001 Dec; 921(1-2):31-43. PubMed ID: 11720709
[TBL] [Abstract][Full Text] [Related]
37. The protective underlying mechanisms of Schisandrin on SH-SY5Y cell model of Alzheimer's disease.
Zhao ZY; Zhang YQ; Zhang YH; Wei XZ; Wang H; Zhang M; Yang ZJ; Zhang CH
J Toxicol Environ Health A; 2019; 82(19):1019-1026. PubMed ID: 31739764
[TBL] [Abstract][Full Text] [Related]
38. The retinoic acid and brain-derived neurotrophic factor differentiated SH-SY5Y cell line as a model for Alzheimer's disease-like tau phosphorylation.
Jämsä A; Hasslund K; Cowburn RF; Bäckström A; Vasänge M
Biochem Biophys Res Commun; 2004 Jul; 319(3):993-1000. PubMed ID: 15184080
[TBL] [Abstract][Full Text] [Related]
39. Tau pathology reduction with SM07883, a novel, potent, and selective oral DYRK1A inhibitor: A potential therapeutic for Alzheimer's disease.
Melchior B; Mittapalli GK; Lai C; Duong-Polk K; Stewart J; Güner B; Hofilena B; Tjitro A; Anderson SD; Herman DS; Dellamary L; Swearingen CJ; Sunil KC; Yazici Y
Aging Cell; 2019 Oct; 18(5):e13000. PubMed ID: 31267651
[TBL] [Abstract][Full Text] [Related]
40. RNA Interference Silencing of Glycogen Synthase Kinase 3β Inhibites Tau Phosphorylation in Mice with Alzheimer Disease.
Bian H; Bian W; Lin X; Ma Z; Chen W; Pu Y
Neurochem Res; 2016 Sep; 41(9):2470-80. PubMed ID: 27255602
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
